Integrated Filing — IndAS



General information about company

Scrip Code 544912
NSE Symbol PRASOLCHEM
MSEI Symbol NOTLISTED
ISIN INE455U01024
Name of company PRASOL CHEMICALS LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 02-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 28-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Speciality Chemicals
Start date and time of board meeting 02-11-2026   17:15:00
End date and time of board meeting 02-11-2026   19:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public No
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 18-04-2026
Indicate Company website link for updated RPT policy of the Company https://www.prasolchem.com/wp-content/uploads/2026/04/Policy-on-Related-Party-Transaction.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
NA



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 41,256.60 84,621.20
Other income 84.20 255.30
Total income 41,340.80 84,876.50
2 Expenses
(a) Cost of materials consumed 25,720.30 47,774.40
(b) Purchases of stock-in-trade 4,346.80 13,123.10
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (1,239.70) (5,159.60)
(d) Employee benefit expense 1,445.30 2,774.50
(e) Finance costs 171.30 353.40
(f) Depreciation, depletion and amortisation expense 697.40 1,358.50
(f) Other Expenses
1 Power and Fuel 1,948.00 3,681.90
2 Repairs and Maintenance 251.50 1,017.30
3 Stores and Spares Consumed 331.00 623.90
4 Labour Charges 268.50 496.80
5 Other Manufacturing Expenses 738.50 1,664.20
6 Selling and Distribution Expenses 1,224.50 2,923.30
7 Other Misc Expenses 445.40 897.00
Total other expenses 5,207.40 11,304.40
Total expenses 36,348.80 71,528.70
3 Total profit before exceptional items and tax 4,992.00 13,347.80
4 Exceptional items 0.00 0.00
5 Total profit before tax 4,992.00 13,347.80
6 Tax expense
7 Current tax 1,184.90 3,400.80
8 Deferred tax 9.60 47.20
9 Total tax expenses 1,194.50 3,448.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 3,797.50 9,899.80
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 3,797.50 9,899.80
17 Other comprehensive income net of taxes (36.70) (21.70)
18 Total Comprehensive Income for the period 3,760.80 9,878.10
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,183.70 1,183.70
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 6.52 17.03
Diluted earnings (loss) per share from continuing operations 6.52 17.03
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 6.52 17.03
Diluted earnings (loss) per share from continuing and discontinued operations 6.52 17.03
24 Debt equity ratio 0.1100 0.1100
25 Debt service coverage ratio 7.1400 7.7600
26 Interest service coverage ratio 0.2800 0.3700
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above unaudited standalone results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on November 02, 2026. The Limited Review, as required under Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been carried out by the Statutory Auditors for the quarter and half year ended September 30, 2026, and they have issued an unmodified limited review report on the same. 2. The aforesaid financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter. 3. The Company has only one primary reportable segment, which is Specialty Chemicals. Accordingly, no separate disclosures of segment information have been made. 4. During the quarter ended September 30, 2026, the Company has completed its Initial Public Offer (IPO) of 7,396,437 equity shares of face value of Rs. 2 each at an issue price of Rs. 676 per share, aggregating to Rs. 5,000 Million. Pursuant to IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on September, 16, 2026. The issue comprised of offer for sale of 62,13,006 Equity shares by selling shareholders aggregating to Rs. 4,200 Million and fresh issue of 1,183,431 equity shares aggregating to Rs. 800 Million. Accordingly, 1,183,431 equity shares were allotted on September 11, 2026 to shareholders. Further, expenses relating the IPO ( net of share of selling shareholders) of Rs. 29.27 Million have been adjusted against Securities Premium Account. 5. The financial results including cash flow statements for the quarter and Half year ended September 30 , 2025 have been approved by the Board of Directors but have not been subject to limited review or audit. However, the management has exercised necessary diligence to ensure that the financial results for the said quarter provide a true and fair view of the Company’s affairs.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 31,433.50
Capital work-in-progress 7,022.30
Investment property 0.00
Goodwill 0.00
Other intangible assets 316.30
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 0.00
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other Financial Assets 272.20
2 Other Non-Current Assets 131.00
Total of other non-current financial assets 403.20
Total non-current financial assets 403.20
Deferred tax assets (net)
Other non-current assets
Total of other non-current assets
Total non-current assets 39,175.30
2 Current assets
Inventories 30,113.30
Current financial asset
Current investments 0.00
Trade receivables, current 35,195.20
Cash and cash equivalents 485.90
Bank balance other than cash and cash equivalents 13.70
Loans, current 0.00
Other current financial assets
Total of other current financial assets 2,092.10
Total current financial assets 37,786.90
Current tax assets (net)
Other current assets
Total of other current assets
Total current assets 67,900.20
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 1,07,075.50
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,183.70
Other equity 60,556.20
Total equity attributable to owners of parent 61,739.90
Non controlling interest
Total equity 61,739.90
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease Liabilities 40.80
Total of other non-current financial liabilities 40.80
Total non-current financial liabilities 40.80
Provisions, non-current 1,063.60
Deferred tax liabilities (net) 2,640.10
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 3,744.50
Current liabilities
Current financial liabilities
Borrowings, current 6,878.70
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 201.50
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 30,252.20
Total Trade payable 30,453.70
Other current financial liabilities
1 Lease Liabilities 4.80
Total of other current financial liabilities 4.80
Total current financial liabilities 37,337.20
Other current liabilities 2,623.40
1 Other Financial Liabilities 669.20
2 Other Current Liabilities 1,954.20
Total of other current liabilities 2,623.40
Provisions, current 231.50
Current tax liabilities (Net) 1,399.00
Deferred government grants, Current
Total current liabilities 41,591.10
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 45,335.60
Total equity and liabilites 1,07,075.50
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss - Remeasurement (gain)/losses on defined benefit plans (49.00) (29.00)
Total Amount of items that will not be reclassified to profit and loss (49.00) (29.00)
2 Income tax relating to items that will not be reclassified to profit or loss (12.30) (7.30)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income (36.70) (21.70)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 13,347.80
Adjustments for reconcile profit (loss)
Adjustments for finance costs 318.90
Adjustments for decrease (increase) in inventories (14,789.50)
Adjustments for decrease (increase) in trade receivables, current (7,346.90)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (46.80)
Adjustments for decrease (increase) in other non-current assets 4.10
Adjustments for other financial assets, non-current (31.30)
Adjustments for other financial assets, current (536.90)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 9,691.70
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (1,108.80)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,358.50
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 39.10
Adjustments for provisions, non-current 70.90
Adjustments for other financial liabilities, current (76.70)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (61.50)
Adjustments for dividend income 0.00
Adjustments for interest income 15.80
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 43.90
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (12,487.10)
Net cash flows from (used in) operations 860.70
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 2,032.10
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (1,171.40)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 7.80
Purchase of property, plant and equipment 3,632.20
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 15.80
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (3,608.60)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 8,000.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 1,89,436.50
Repayments of borrowings 1,93,564.20
Payments of lease liabilities 0.00
Dividends paid 696.00
Interest paid 317.40
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 2,858.90
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (1,921.10)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (1,921.10)
Cash and cash equivalents cash flow statement at beginning of period 2,407.00
Cash and cash equivalents cash flow statement at end of period 485.90





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 C N K & Associates LLP Yes 31-07-2027


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Public Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 11-09-2026
Amount Raised 8,000.00
Report filed for Quarter ended 30-09-2026
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NA
Comments of the Audit Committee after review NA
Comments of the auditors, if any NA
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any


Signatory Details

Name of signatory Kiran Rajendra Agrawal
Designation of person Company Secretary and Compliance Officer
Place Navi Mumbai
Date 02-11-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Prasol Chemicals Limited Nishith Shah Whole-time Director Remuneration 33,00,00,000.00 Audit Committee granted Omnibus Approval 16,21,24,544.00 12,39,57,895.90 3,01,28,545.90
2 Prasol Chemicals Limited Gaurang Parikh Managing Director Remuneration 23,65,00,000.00 Audit Committee granted Omnibus Approval 11,48,67,095.00 8,74,37,273.90 2,14,33,216.70
3 Prasol Chemicals Limited Dhaval Parikh Joint Managing Director Remuneration 18,15,00,000.00 Audit Committee granted Omnibus Approval 8,68,60,166.50 6,35,66,690.60 1,82,20,167.20
4 Prasol Chemicals Limited Pankil Dharia Whol-time Director Remuneration 11,55,00,000.00 Audit Committee granted Omnibus Approval 5,55,03,200.00 4,18,95,937.00 1,13,83,148.20
5 Prasol Chemicals Limited Consolidated Chemequip (Mfr) Private Limited (formally known as Friends Fab Form Private Limited) Common Directorship & shareholder (NRS)/ Relatives of NRS are shareholders Purchase of fixed assets 2,00,00,00,000.00 Audit Committee granted Omnibus Approval 14,19,30,000.00 (2,60,64,000.00) (5,85,84,900.00)
6 Prasol Chemicals Limited Heat Fabs Relative of NRS is/are partner(s) Purchase of fixed assets 2,00,00,00,000.00 Audit Committee granted Omnibus Approval 6,06,20,075.00 1,480.00 2,81,91,540.00
7 Prasol Chemicals Limited Heat Fabs Relative of NRS is/are partner(s) Purchase of goods or services 2,50,00,000.00 Audit Committee granted Omnibus Approval 8,28,000.00 0.00 0.00
8 Prasol Chemicals Limited Maxima FRP Product Promoter (Kunal Dharia) & his relatives are partners Sale of goods or services 2,50,00,000.00 Audit Committee granted Omnibus Approval 15,20,000.00 (12,27,200.00) (18,880.00)
9 Prasol Chemicals Limited Maxima FRP Product Promoter (Kunal Dharia) & his relatives are partners Purchase of fixed assets 10,00,00,000.00 Audit Committee granted Omnibus Approval 1,50,02,872.30 1,64,49,200.00 1,16,00,890.00
10 Prasol Chemicals Limited Maxima FRP Product Promoter (Kunal Dharia) & his relatives are partners Purchase of goods or services 10,00,00,000.00 Audit Committee granted Omnibus Approval 94,24,710.00 0.00 0.00
11 Prasol Chemicals Limited Srinivasan S Independent Director Any other transaction Sitting Fees 0.00 Audit Committee granted Omnibus Approval 35,40,000.00 0.00 22,77,000.00 Textual Information(1)
12 Prasol Chemicals Limited G. Ramakrishnan Independent Director Any other transaction Sitting Fees 0.00 Audit Committee granted Omnibus Approval 23,00,000.00 0.00 0.00 Textual Information(2)
13 Prasol Chemicals Limited Lakshmi Kantam M Independent Director Any other transaction Sitting Fees 0.00 Audit Committee granted Omnibus Approval 37,05,000.00 0.00 2,52,000.00 Textual Information(3)
14 Prasol Chemicals Limited Rahul A Shroff KMP Remuneration 8,80,00,000.00 Audit Committee granted Omnibus Approval 4,33,87,790.00 1,92,52,043.90 84,24,346.60
15 Prasol Chemicals Limited Kiran Agrawal KMP Remuneration 1,75,45,000.00 Audit Committee granted Omnibus Approval 79,61,220.00 0.00 11,95,670.00
16 Prasol Chemicals Limited Kiran Agrawal KMP Any other transaction Ex-gratia 0.00 Audit Committee granted Omnibus Approval 2,50,000.00 0.00 0.00
17 Prasol Chemicals Limited Ajay Jain Independent Director Any other transaction Sitting Fees 0.00 Audit Committee granted Omnibus Approval 51,10,000.00 0.00 23,76,000.00 Textual Information(4)
18 Prasol Chemicals Limited Rakesh Shivaji Jadhav Whol-time Director Remuneration 4,95,00,000.00 Audit Committee granted Omnibus Approval 2,16,52,980.00 0.00 13,40,730.00
19 Prasol Chemicals Limited Rakesh Shivaji Jadhav Whol-time Director Any other transaction Reimbursement of Expenses 1,00,00,000.00 Audit Committee granted Omnibus Approval 30,22,640.00 0.00 0.00
20 Prasol Chemicals Limited Narayan Nair Independent Director Any other transaction Sitting Fees 0.00 Audit Committee granted Omnibus Approval 13,50,000.00 0.00 0.00 Textual Information(5)
21 Prasol Chemicals Limited Galaxy Chemicals (REGD) Independent Director - G. Ramakrishnan is a Partner Sale of goods or services 10,00,00,000.00 Audit Committee granted Omnibus Approval 84,33,750.00 0.00 0.00
Total value of transaction during the reporting period 74,93,94,042.80



Text Block

Textual Information(1) Omnibus approval not applicable
Textual Information(2) Omnibus approval not applicable
Textual Information(3) Omnibus approval not applicable
Textual Information(4) Omnibus approval not applicable
Textual Information(5) Omnibus approval not applicable